Archives

Oegstgeest, December 7, 2021 – ISA’s very own Chief Scientific Officer, Cornelis “Kees” Melief, M.D., Ph.D., will be presenting key learnings in cancer vaccine development in an educational session at the ESMO Immune-Oncology Congress 2021, taking place on 8th – 11th December 2021 in Geneva, Switzerland and online.

Key learnings include:

Direct correlation between strength of cancer vaccine-induced immune response and clinical responseCombination therapy of cancer vaccine with standard of care and/or checkpoint blockers necessary for improved outcomes in treatment of late stage cancers

Session: New indications in head and neck (H&N) cancer (incl anaplastic thyroid) (ID 8)Presentation title: HPV vaccination for H&N